Protagonist Therapeutics (PTGX) Competitors $56.32 +0.98 (+1.77%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. RDY, ASND, MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, VRNA, and BBIOShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Revolution Medicines Verona Pharma BridgeBio Pharma Protagonist Therapeutics (NASDAQ:PTGX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings. Which has stronger valuation & earnings, PTGX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Protagonist Therapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$207.80M16.80-$78.96M$0.7575.09Dr. Reddy's Laboratories$325.54B0.04$668M$0.6624.45 Which has more risk & volatility, PTGX or RDY? Protagonist Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Do analysts prefer PTGX or RDY? Protagonist Therapeutics currently has a consensus target price of $65.44, suggesting a potential upside of 16.20%. Dr. Reddy's Laboratories has a consensus target price of $16.95, suggesting a potential upside of 5.02%. Given Protagonist Therapeutics' higher possible upside, equities analysts clearly believe Protagonist Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to PTGX or RDY? In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 8 articles in the media. Protagonist Therapeutics' average media sentiment score of 0.80 beat Dr. Reddy's Laboratories' score of 0.26 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is PTGX or RDY more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Dr. Reddy's Laboratories' net margin of 17.25%. Protagonist Therapeutics' return on equity of 34.68% beat Dr. Reddy's Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics52.76% 34.68% 30.98% Dr. Reddy's Laboratories 17.25%17.87%12.32% Does the MarketBeat Community believe in PTGX or RDY? Dr. Reddy's Laboratories received 31 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. However, 61.55% of users gave Protagonist Therapeutics an outperform vote while only 59.56% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformProtagonist TherapeuticsOutperform Votes29361.55% Underperform Votes18338.45% Dr. Reddy's LaboratoriesOutperform Votes32459.56% Underperform Votes22040.44% Do institutionals & insiders have more ownership in PTGX or RDY? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryProtagonist Therapeutics beats Dr. Reddy's Laboratories on 12 of the 16 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49B$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio21.178.6727.1419.96Price / Sales16.80262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book9.646.597.064.69Net Income-$78.96M$143.75M$3.23B$248.14M7 Day Performance4.65%3.72%2.67%2.39%1 Month Performance24.41%11.01%8.82%6.05%1 Year Performance65.79%3.87%31.44%13.60% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.0116 of 5 stars$56.32+1.8%$65.44+16.2%+63.0%$3.49B$207.80M21.17120Insider TradeRDYDr. Reddy's Laboratories1.4905 of 5 stars$14.73+0.0%$17.00+15.4%+10.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.5574 of 5 stars$175.69+7.9%$216.07+23.0%+30.2%$10.71B$368.70M-24.75640Analyst ForecastAnalyst RevisionMRNAModerna4.4595 of 5 stars$27.05+1.8%$53.58+98.1%-81.3%$10.46B$3.14B-2.913,900VTRSViatris2.5476 of 5 stars$8.69-1.1%$10.50+20.8%-15.6%$10.20B$14.33B-11.7437,000QGENQiagen3.2034 of 5 stars$44.89-0.5%$48.42+7.9%+9.2%$9.98B$2.00B125.006,030BPMCBlueprint Medicines1.1596 of 5 stars$127.79+26.1%$125.69-1.6%+21.4%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.4301 of 5 stars$11.17+1.6%$17.50+56.7%+6.7%$7.97B$29.05M-74.46860RVMDRevolution Medicines4.4427 of 5 stars$40.65+3.2%$67.08+65.0%+4.5%$7.57B$742K-11.32250Positive NewsVRNAVerona Pharma2.3609 of 5 stars$84.10+3.6%$82.13-2.3%+573.5%$6.82B$118.54M-43.8030Positive NewsAnalyst ForecastAnalyst RevisionBBIOBridgeBio Pharma4.6256 of 5 stars$35.46+3.5%$57.09+61.0%+42.1%$6.73B$127.42M-12.44400Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Verona Pharma Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTGX Stock Free PTGX Stock Alerts